Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
OCS is expected to report earnings to rise 152.69% to -40 cents per share on November 05
Q3'26
Est.
$-0.40
Q2'26
Beat
by $0.23
Q1'26
Beat
by $0.08
Q3'25
Beat
by $0.14
Q2'25
Missed
by $0.03
The last earnings report on August 06 showed earnings per share of -15 cents, beating the estimate of -39 cents. With 105.00K shares outstanding, the current market capitalization sits at 715.20M.